Verrica Says Development Partner Receives Japanese Approval For Ycanth; Shares Rise Pre-Bell

MT Newswires Live

09/19

Verrica Pharmaceuticals (VRCA) said Friday that its development partner, Torii Pharmaceutical, has received approval from the Japanese Ministry of Health, Labour and Welfare for Ycanth, a drug-device combination product for the treatment of molluscum contagiosum.

The approval of Ycanth in Japan triggered a one-time $10 million milestone cash payment which Verrica Pharmaceuticals said it expects to receive in coming weeks.

Looking ahead, the dermatology therapeutics company said it expects to begin patient dosing in the US by the end of 2025 for its global phase 3 trial to study Ycanth for the treatment of common warts.

Shares of Verrica Pharmaceuticals were up 14% in recent Friday premarket activity.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2568926350"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2568926350\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2568926350?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-19 20:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2568926350","market":"us","top_or_hot":-1,"title":"Verrica Says Development Partner Receives Japanese Approval For Ycanth; Shares Rise Pre-Bell","media":"MT Newswires Live","content":"<html><body><p> Verrica Pharmaceuticals (VRCA) said Friday that its development partner, Torii Pharmaceutical, has received approval from the Japanese Ministry of Health, Labour and Welfare for Ycanth, a drug-device combination product for the treatment of molluscum contagiosum.</p><p>The approval of Ycanth in Japan triggered a one-time $10 million milestone cash payment which Verrica Pharmaceuticals said it expects to receive in coming weeks.</p><p>Looking ahead, the dermatology therapeutics company said it expects to begin patient dosing in the US by the end of 2025 for its global phase 3 trial to study Ycanth for the treatment of common warts.</p><p>Shares of Verrica Pharmaceuticals were up 14% in recent Friday premarket activity.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Verrica Says Development Partner Receives Japanese Approval For Ycanth; Shares Rise Pre-Bell</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVerrica Says Development Partner Receives Japanese Approval For Ycanth; Shares Rise Pre-Bell\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-09-19 20:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Verrica Pharmaceuticals (VRCA) said Friday that its development partner, Torii Pharmaceutical, has received approval from the Japanese Ministry of Health, Labour and Welfare for Ycanth, a drug-device combination product for the treatment of molluscum contagiosum.</p><p>The approval of Ycanth in Japan triggered a one-time $10 million milestone cash payment which Verrica Pharmaceuticals said it expects to receive in coming weeks.</p><p>Looking ahead, the dermatology therapeutics company said it expects to begin patient dosing in the US by the end of 2025 for its global phase 3 trial to study Ycanth for the treatment of common warts.</p><p>Shares of Verrica Pharmaceuticals were up 14% in recent Friday premarket activity.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VRCA","symbol_name":"Verrica Pharmaceuticals Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2568926350","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2568926350","pubTimestamp":1758285308,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Verrica Pharmaceuticals  said Friday that its development partner, Torii Pharmaceutical, has received approval from the Japanese Ministry of Health, Labour and Welfare for Ycanth, a drug-device combination product for the treatment of molluscum contagiosum.The approval of Ycanth in Japan triggered a one-time $10 million milestone cash payment which Verrica Pharmaceuticals said it expects to receive in coming weeks.Looking ahead, the dermatology therapeutics company said it expects to begin patient dosing in the US by the end of 2025 for its global phase 3 trial to study Ycanth for the treatment of common warts.Shares of Verrica Pharmaceuticals were up 14% in recent Friday premarket activity.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VRCA":"Verrica Pharmaceuticals Inc.","BK4007":"制药"},"translate_title":"Verrica表示开发合作伙伴获得日本对Ycanth的批准；盘前股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VRCA":1},"content_text":"Verrica Pharmaceuticals (VRCA) said Friday that its development partner, Torii Pharmaceutical, has received approval from the Japanese Ministry of Health, Labour and Welfare for Ycanth, a drug-device combination product for the treatment of molluscum contagiosum.The approval of Ycanth in Japan triggered a one-time $10 million milestone cash payment which Verrica Pharmaceuticals said it expects to receive in coming weeks.Looking ahead, the dermatology therapeutics company said it expects to begin patient dosing in the US by the end of 2025 for its global phase 3 trial to study Ycanth for the treatment of common warts.Shares of Verrica Pharmaceuticals were up 14% in recent Friday premarket activity.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}